{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:25:46Z","timestamp":1761920746476,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.msard.2020.102253","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T11:46:10Z","timestamp":1591098370000},"page":"102253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Can multiple sclerosis be cured? A case of highly active relapsing multiple sclerosis treated with autologous hematopoietic stem-cell transplantation 13 years ago"],"prefix":"10.1016","volume":"44","author":[{"given":"Jan","family":"Lycke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"Bone Marrow Transplant","year":"2019","author":"Sharrack","key":"10.1016\/j.msard.2020.102253_bib0001"},{"issue":"2","key":"10.1016\/j.msard.2020.102253_bib0002","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial","volume":"321","author":"Burt","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.msard.2020.102253_bib0003","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102253_bib0004","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10072-018-3670-1","article-title":"Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis","volume":"40","author":"Ge","year":"2019","journal-title":"Neurol. Sci."},{"issue":"22","key":"10.1016\/j.msard.2020.102253_bib0005","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102253_bib0006","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol."},{"issue":"10044","key":"10.1016\/j.msard.2020.102253_bib0007","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2020.102253_bib0008","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jnnp-2018-319446","article-title":"Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis","volume":"90","author":"Moore","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2020.102253_bib0009","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaneurol.2014.3780","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report","volume":"72","author":"Nash","year":"2015","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102253_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102253_bib0011","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"Pt 5","key":"10.1016\/j.msard.2020.102253_bib0012","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/brain\/122.5.871","article-title":"Development of a multiple sclerosis functional composite as a clinical trial outcome measure","volume":"122","author":"Cutter","year":"1999","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2020.102253_bib0013","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.acn.2005.07.003","article-title":"Normative Symbol Digit Modalities Test performance in a community-based sample","volume":"21","author":"Sheridan","year":"2006","journal-title":"Arch. Clin. Neuropsychol."},{"issue":"5","key":"10.1016\/j.msard.2020.102253_bib0014","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","article-title":"Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF","volume":"67","author":"Rosengren","year":"1996","journal-title":"J. Neurochem."},{"issue":"9","key":"10.1016\/j.msard.2020.102253_bib0015","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","article-title":"Neurofilament and glial fibrillary acidic protein in multiple sclerosis","volume":"63","author":"Norgren","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2020.102253_bib0016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0165-0270(94)90011-6","article-title":"A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults","volume":"51","author":"Rosengren","year":"1994","journal-title":"J. Neurosci. Methods"},{"issue":"3","key":"10.1016\/j.msard.2020.102253_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2013a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol","year":"1990","journal-title":"Health Policy"},{"issue":"199","key":"10.1016\/j.msard.2020.102253_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ane.12425","article-title":"The Swedish MS registry - clinical support tool and scientific resource","volume":"132","author":"Hillert","year":"2015","journal-title":"Acta Neurol. Scand."},{"issue":"Pt 5","key":"10.1016\/j.msard.2020.102253_bib0019","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2020.102253_bib0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab","volume":"69","author":"Gunnarsson","year":"2011","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102253_bib0021","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1352458516639384","article-title":"Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis","volume":"23","author":"Novakova","year":"2017","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2020.102253_bib0022","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820303291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820303291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:56:01Z","timestamp":1761900961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820303291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":22,"alternative-id":["S2211034820303291"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102253","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can multiple sclerosis be cured? A case of highly active relapsing multiple sclerosis treated with autologous hematopoietic stem-cell transplantation 13 years ago","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102253"}}